

Saskatchewan Biosimilars Initiative

Concluded Transition Periods

Drug Plan and Extended Benefits Branch
 3475 Albert Street
 REGINA SK S4S 6X6
 Phone: 1-800-667-7581 (306-787-3317 in Regina)
 Email: sk.biosimilars@health.gov.sk.ca

Drug name	Reference biologic brand name (switch from)	Biosimilar brand name (switch to)	Health conditions
End of Transition Period: April 30, 2023			
Adalimumab	Humira®	Abrilada® Amgevita™ Hadlima® Hulio® Hyrimoz® Idacio® Simlandi™ Yuflyma™	Auto-immune conditions, including: Ankylosing spondylitis Crohn's disease Hidradenitis suppurativa Juvenile idiopathic arthritis Plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis Uveitis
Enoxaparin	Lovenox®	Inclunox® Noromby® Redesca™	Prevention and treatment of venous thromboembolic events
Etanercept	Enbrel®	Brenzys® Erelzi®	Auto-immune conditions, including: Ankylosing spondylitis Juvenile idiopathic arthritis Plaque psoriasis Psoriatic arthritis Rheumatoid arthritis
Filgrastim	Neupogen®	Grastofil® Nivestym™	Low white blood cell count (non-cancer related)
Glatiramer (a non-biologic complex drug)	Copaxone®	Glatect™	Multiple sclerosis
Infliximab	Remicade®	Avsola™ Inflectra® Renflexis™	Auto-immune conditions, including: Ankylosing spondylitis Crohn's disease Plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis
Insulin aspart	NovoRapid® (cartridge)	Kirsty® Trurapi®	Diabetes
Insulin glargine	Lantus® (cartridge, pre-filled pens)	Basaglar™ Semglee®	Diabetes
Rituximab	Rituxan®	Riximyo® Ruxience™ Truxima™	Auto-immune conditions listed in Appendix A of the Saskatchewan Formulary